HK Stock Market Move | ASMPT(00522) rose by more than 5%, and its wholly-owned subsidiary will become a key shareholder of Shenzhen Original Advanced Compounds, effectively promoting international cooperation in the semiconductor industry.
ASM Pacific Technology (00522) rose more than 5%, reaching 6.60% as of the time of writing, at 75.95 Hong Kong dollars, with a turnover of 4.95 billion Hong Kong dollars.
ASM Pacific Technology (00522) rose by over 5%, rising to 6.60% at the time of publication, reaching HK$75.95 with a trading volume of HK$4.95 billion.
On the news front, Shenzhen Original Advanced Compounds recently announced that the China Securities Regulatory Commission has approved the company's major asset restructuring plan. In this restructuring, Shenzhen Original Advanced Compounds intends to acquire 87.47% of the equity of Advanced Packaging Materials International Limited (AAMI) for a consideration of RMB 3.069 billion, while divesting its traditional cable material business and introducing ASM Pacific Technology's wholly-owned subsidiary, ASMPT Holding, as an important shareholder.
Media reports suggest that this is seen as a pioneering demonstration of A-share listed companies bringing in international semiconductor leaders, which will effectively promote international cooperation in the semiconductor industry. EB SECURITIES International stated that under the expectation of loose monetary policy, the valuation and profit potential of Hong Kong stocks are favored by the market, especially leading companies in the technology, finance, and consumer industries, which are expected to see more active performance under the favorable policies and funding support.
Related Articles

Guangdong Taienkang Pharmaceutical (301263.SZ): The application for the registration and listing approval of sulfamethoxazole tablets has been accepted.

SoftBank (SFTBY.US) and OpenAI's Japan AI joint venture plan has been reported to be delayed, with new developments expected to be announced in November.

Guotai Haitong: Initiates "buy" rating on BEST PACIFIC (02111) with a target price of HK$4.42.
Guangdong Taienkang Pharmaceutical (301263.SZ): The application for the registration and listing approval of sulfamethoxazole tablets has been accepted.

SoftBank (SFTBY.US) and OpenAI's Japan AI joint venture plan has been reported to be delayed, with new developments expected to be announced in November.

Guotai Haitong: Initiates "buy" rating on BEST PACIFIC (02111) with a target price of HK$4.42.
